A 46-year-old man with advanced lung cancer recovered after doctors used Next Generation Sequencing to identify a rare ALK fusion mutation and treat him with targeted therapy instead of chemotherapy.
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received ...
News-Medical.Net on MSN
Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback